Contineum Therapeutics (CTNM) said Monday the US Food and Drug Administration approved its investigational new drug application for PIPE-791 to treat chronic pain related to osteoarthritis and low back pain.
The phase 1b trial to potentially treat the two indications is expected to start in Q1 2025, the company said, adding it expects to enroll about 40 people at up to five sites.
Topline results from the trial are expected in early 2026, Contineum said.
Price: 16.50, Change: -0.71, Percent Change: -4.13
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。